---
Commercialization

Commercialization:

Revenue generation: near-term through a limited number of wholly owned clinics in Europe and also through out-licencing partnerships into the US addiction treatment clinic industry; medium-term revenue generation through therapeutics commercialization.

Clinics

Build the platform to deploy the therapeutics developed in our R&D business while generating clinical data and revenue and treating clients.

  • Awakn has 3 clinics operational: London (UK), Bristol (UK), Oslo (Norway)
  • Our target is 15 - 20 clinics
  • We provide treatments programs for addiction and mental health conditions such as depression and PTSD
  • Each clinic will generate approximately CA$5m per annum

Commercialization: Therapeutics Commercialization

Enable third party addiction treatment centres deploy more effective treatments to patients.

Purpose:

To commercialize our proprietary Ketamine-assisted therapy package for the treatment of AUD beyond our physical footprint. Disrupting the North American addiction treatment market through licensing our ground breaking therapeutics package

Licensing partnerships outside UK and Europe for the Awakn KARE methodology

Proposition:

Access to KARE proprietary IP
Training
Systems
Clinic design and new-site activation support

Target Audience:

Existing addiction treatment clinic’s throughout the US and Canada

Sign Up for Newsletter

Awakn_logo_corp

MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom

UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow